British Journal of Clinical Pharmacology

Off-label and unlicensed prescribing for children: have we made any progress?
pp. 1-2(2)
Author: Waller, D. G.

Population pharmacokinetic and pharmacodynamic models of remifentanil in healthy volunteers using artificial neural network analysis
pp. 3-13(11)
Authors: Kang, S. H.; Poynton, M. R.; Kim, K. M.; Lee, H.; Kim, D. H.; Lee, S. H.; Bae, K. S.; Linares, O.; Kern, S. E.; Noh, G. J.

The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example
pp. 14-26(13)
Authors: Dickinson, Gemma L.; Lennard, Martin S.; Tucker, Geoffrey T.; Rostami-Hodjegan, Amin

A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation
pp. 27-35(9)
Authors: Conil, Jean Marie; Georges, Bernard; Lavit, Michel; Laguerre, Jacky; Samii, Kamram; Houin, Georges; Saivin, Sylvie

Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease
pp. 36-48(13)
Authors: Lehr, Thorsten; Staab, Alexander; Tillmann, Christiane; Trommeshauser, Dirk; Raschig, Andreas; Schaefer, Hans Guenter; Kloft, Charlotte

Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia
pp. 49-56(8)
Authors: Tang, Yi-lang; Mao, Peixian; Li, Feng-Min; Li, Wenbiao; Chen, Qi; Jiang, Feng; Cai, Zhuo-ji; Mitchell, Philip B.

Pharmacogenetic interactions of three candidate gene polymorphisms with ACE-inhibitors or β-blockers and the risk of atherosclerosis
pp. 57-66(10)
Authors: Schelleman, H.; Klungel, O. H.; Witteman, J. C. M.; Hofman, A.; van Duijn, C. M.; de Boer, A.; Stricker, B. H. CH.

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects
pp. 67-74(8)
Authors: Zhang, Yifan; Si, Dayong; Chen, Xiaoyan; Lin, Nan; Guo, Yingjie; Zhou, Hui; Zhong, Dafang

Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain
pp. 75-82(8)
Authors: Forst, Thomas; Smith, Terry; Schütte, Klemens; Marcus, Paul; Pfützner, Andreas

Do calcium antagonists contribute to gastro-oesophageal reflux disease and concomitant noncardiac chest pain?
pp. 83-89(7)
Authors: Hughes, Jeff; Lockhart, Judith; Joyce, Andrew

Attitudes and experiences of community pharmacists towards paediatric off-label prescribing: a prospective survey
pp. 90-95(6)
Authors: Stewart, Derek; Rouf, Abdul; Snaith, Ailsa; Elliott, Kathleen; Helms, Peter J.; McLay, James S.

No association between CYP2D6 polymorphisms and personality trait in Japanese
pp. 96-99(4)
Authors: Iwashima, Kumiko; Yasui-Furukori, Norio; Kaneda, Ayako; Saito, Manabu; Nakagami, Taku; Sato, Yasushi; Kaneko, Sunao

Trends over 5 years in cardiovascular medicine use in Australian veterans with diabetes
pp. 100-104(5)
Authors: Roughead, Elizabeth E.; Pratt, Nicole; Gilbert, Andrew L.

Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years: a population analysis
pp. 105-109(5)
Authors: Jullien, V.; Raïs, A.; Urien, S.; Dimet, J.; Delaugerre, C.; Bouillon-Pichault, M.; Rey, E.; Pons, G.; Blanche, S.; Tréluyer, J. M.

Risk of stent thrombosis after sirolimus or paclitaxel eluting coronary stent implantation
pp. 110-112(3)
Authors: Moreno, Raul; Fernandez, Cristina; Sanchez-Recalde, Angel; Calvo, Luis; Galeote, Guillermo; Sanchez-Aquino, Rosa; Lopez-Sendon, Jose-Luis

Glimepiride-induced vasculitis: a case report
pp. 113-114(2)
Authors: Ben Salem, Chaker; Hmouda, Houssem; Bouraoui, Kamel

Oxford Handbook of Nurse Prescribing
pp. 115-115(1)

John Trounce
pp. 116-117(2)
Author: Spector, Roy G.

Erratum
pp. 118-118(1)